Tissue Diagnostic Market to Record Overwhelming Hike in Revenues by 2026
Tissue
diagnosis is important tool in diagnosis, monitoring, and
management of different types of cancer conditions. Recognition of
sign and symptoms of disease are done through biopsy, a process of
taking sample from region of interest such as skin, tissue or tumor
for further diagnosis. Biopsy are primarily done to look for cancer
detection or to detect rejection of transplanted organ draft.
Biopsy is done to
identify likely cause of cancerous and non-cancerous tissue, which
are unable to detect through CT-scan or X-rays. Depending on area of
sample collection various biopsy procedures are done such as
endoscopic biopsy, bone marrow biopsy, skin biopsy, kidney biopsy,
liver biopsy, and prostate biopsy. Furthermore biopsy can be done
using needle biopsy, CT guided biopsy, Ultrasound biopsy, and
surgical biopsy for the tissue diagnostic. According to the American
journal of Nephrology, 2015, Australia has the highest numbers of
annual renal biopsy rates (215 persons/million person/year) followed
by the Finland (176 persons/million person/year) and U.S. (175
persons/million person/year). The increased numbers of biopsy
procedure likely to fuel the growth of tissue diagnostic market, in
near future.
Rising prevalence of
different cancer incidences is major driving factor boosting the
tissue diagnostic market. According to American cancer Society (ACS),
1.6 million new cases of cancer diagnosed in the U.S., in 2016. In
addition, increase research funding in cancer treatment and growing
healthcare expenditure likely to show gradual rise in tissue
diagnostic market. National Cancer Institute, in 2015, spends US$
4,480 million on various types of cancer research which includes
breast cancer, colorectal cancer, cervical cancer, liver cancer, lung
cancer, leukemia, ovarian cancer and uterine cancer.
Tissue diagnostic
market taxonomy:
By Product Type:
Instruments
Tissue
processors
Microtomes
Cryostats
Slide
warmers
Paraffin
dispenser
Biological
microscopes
Embedded
center modules
Strainers
Consumables
Stains
Paraffin
Cassettes
Autopsy &
dissection
Slides
By Technology:
In situ
hybridization
Digital
pathology
Immunohistochemistry
Tissue
microarray
Special staining
By Disease:
Breast cancer
Lymphoma cancer
Gastric cancer
Prostate cancer
By End user:
Research
laboratories
Hospitals
Contract
research organizations
Inquire Here
Before Purchase of Research Report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/1112
Rise in the
prevalence of cancer incidences to boost the tissue diagnostic market
According to the
United States Cancer statistics report published in 2014 by Centers
of Disease Control and Prevention (CDC), between 1999 and 2014, more
than 1600 people a day, died due to the cause of cancer. Although
screening tests helps to detect cancer condition at early stage, data
from Healthy People 2020, an initiative form Department of Health and
Human Services, reveals that screening rate is still below the
national targets set. Combined data collected from CDC and National
cancer institute (NCI) focus on the top 3 cancer incidences in male
and female. In male prostate cancer incidence are higher, while in
females breast cancer are most dominated, followed by lung and colon
cancer respectively in both male and female.
New and advanced
methods of tissue diagnosis favors the market growth
Innovation in tissue
diagnostic process for the efficient diagnostic testing such as
Fluorescence in situ hybridization (FISH), Immunohistochemistry (IHC)
and In situ hybridization (ISH) raises the opportunity to grow tissue
diagnostic market in future. In September 2017, researchers at the
University of Texas, developed a new way of diagnosis by creating pen
named as “MasSpec Pen”, which is handheld devices able to
distinguish healthy tissue and tumor tissue in just 10 seconds, more
than 150 times quicker than existing technology. These new tool
provides improvement in cancer treatment and minimizes the chances of
recurrence by offering precise diagnostic information, which
eventually favors the growth in tissue diagnostic market.
Key players operated
in the tissue diagnostic market are Biocare Medical, Agilent
technologies, Thermo Fisher Scientific, Sigma-Aldrich, Roche
Diagnostics, Danaher corp., Biogenex Laboratories, Life Technologies
and Abbott laboratories.
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel:
+1-206-701-6702
Comments
Post a Comment